<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">PLoS One</journal-id>
      <journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id>
      <journal-id journal-id-type="publisher-id">plos</journal-id>
      <journal-id journal-id-type="pmc">plosone</journal-id>
      <journal-title-group>
        <journal-title>PLoS ONE</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1932-6203</issn>
      <publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, CA USA</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26186352</article-id>
      <article-id pub-id-type="pmc">4505893</article-id>
      <article-id pub-id-type="doi">10.1371/journal.pone.0132736</article-id>
      <article-id pub-id-type="publisher-id">PONE-D-15-10264</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Novel <italic>ZEB2-BCL11B</italic> Fusion Gene Identified by RNA-Sequencing in Acute Myeloid Leukemia with t(2;14)(q22;q32)</article-title>
        <alt-title alt-title-type="running-head"><italic>ZEB2-BCL11B</italic> Fusion Gene in Acute Myeloid Leukemia</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Torkildsen</surname>
            <given-names>Synne</given-names>
          </name>
          <xref ref-type="aff" rid="aff001">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff002">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff003">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gorunova</surname>
            <given-names>Ludmila</given-names>
          </name>
          <xref ref-type="aff" rid="aff001">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff002">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Beiske</surname>
            <given-names>Klaus</given-names>
          </name>
          <xref ref-type="aff" rid="aff004">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tj&#xF8;nnfjord</surname>
            <given-names>Geir E.</given-names>
          </name>
          <xref ref-type="aff" rid="aff003">
            <sup>3</sup>
          </xref>
          <xref ref-type="aff" rid="aff005">
            <sup>5</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Heim</surname>
            <given-names>Sverre</given-names>
          </name>
          <xref ref-type="aff" rid="aff001">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff002">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff005">
            <sup>5</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Panagopoulos</surname>
            <given-names>Ioannis</given-names>
          </name>
          <xref ref-type="aff" rid="aff001">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff002">
            <sup>2</sup>
          </xref>
          <xref rid="cor001" ref-type="corresp">*</xref>
        </contrib>
      </contrib-group>
      <aff id="aff001">
        <label>1</label>
        <addr-line>Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway</addr-line>
      </aff>
      <aff id="aff002">
        <label>2</label>
        <addr-line>Centre for Cancer Biomedicine, Faculty of Medicine, University of Oslo, Oslo, Norway</addr-line>
      </aff>
      <aff id="aff003">
        <label>3</label>
        <addr-line>Department of Hematology, Oslo University Hospital, Oslo, Norway</addr-line>
      </aff>
      <aff id="aff004">
        <label>4</label>
        <addr-line>Department of Pathology, Oslo University Hospital, Oslo, Norway</addr-line>
      </aff>
      <aff id="aff005">
        <label>5</label>
        <addr-line>Institute of Clinical Medicine, Medical Faculty, University of Oslo, Oslo, Norway</addr-line>
      </aff>
      <contrib-group>
        <contrib contrib-type="editor">
          <name>
            <surname>Mills</surname>
            <given-names>Ken</given-names>
          </name>
          <role>Editor</role>
          <xref ref-type="aff" rid="edit1"/>
        </contrib>
      </contrib-group>
      <aff id="edit1">
        <addr-line>Queen's University Belfast, UNITED KINGDOM</addr-line>
      </aff>
      <author-notes>
        <fn fn-type="conflict" id="coi001">
          <p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p>
        </fn>
        <fn fn-type="con" id="contrib001">
          <p>Conceived and designed the experiments: ST IP. Performed the experiments: ST LG IP. Analyzed the data: ST LG SH IP. Contributed reagents/materials/analysis tools: ST KB GET SH. Wrote the paper: ST SH IP. Hematological data on the AML patient: ST KB GET.</p>
        </fn>
        <corresp id="cor001">* E-mail: <email>ioannis.panagopoulos@rr-research.no</email></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>17</day>
        <month>7</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2015</year>
      </pub-date>
      <volume>10</volume>
      <issue>7</issue>
      <elocation-id>e0132736</elocation-id>
      <history>
        <date date-type="received">
          <day>9</day>
          <month>3</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>17</day>
          <month>6</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-year>2015</copyright-year>
        <copyright-holder>Torkildsen et al</copyright-holder>
        <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited</license-p>
        </license>
      </permissions>
      <self-uri content-type="pdf" xlink:type="simple" xlink:href="pone.0132736.pdf"/>
      <abstract>
        <p>RNA-sequencing of a case of acute myeloid leukemia with the bone marrow karyotype 46,XY,t(2;14)(q22;q32)[5]/47,XY,idem,+?4,del(6)(q13q21)[cp6]/46,XY[4] showed that the t(2;14) generated a <italic>ZEB2-BCL11B</italic> chimera in which exon 2 of <italic>ZEB2</italic> (nucleotide 595 in the sequence with accession number NM_014795.3) was fused to exon 2 of <italic>BCL11B</italic> (nucleotide 554 in the sequence with accession number NM_022898.2). RT-PCR together with Sanger sequencing verified the presence of the above-mentioned fusion transcript. All functional domains of BCL11B are retained in the chimeric protein. Abnormal expression of <italic>BCL11B</italic> coding regions subjected to control by the <italic>ZEB2</italic> promoter seems to be the leukemogenic mechanism behind the translocation.</p>
      </abstract>
      <funding-group>
        <funding-statement>This work was supported by grants from the Norwegian Cancer Society and the Norwegian Radium Hospital Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
      </funding-group>
      <counts>
        <fig-count count="3"/>
        <table-count count="3"/>
        <page-count count="12"/>
      </counts>
      <custom-meta-group>
        <custom-meta id="data-availability">
          <meta-name>Data Availability</meta-name>
          <meta-value>All data underlying the findings in the study are freely available in the paper and in the Supporting Information.</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
    <notes>
      <title>Data Availability</title>
      <p>All data underlying the findings in the study are freely available in the paper and in the Supporting Information.</p>
    </notes>
  </front>
  <body>
    <sec sec-type="intro" id="sec001">
      <title>Introduction</title>
      <p>Acute myeloid leukemia (AML, also known as acute myelogenous leukemia or acute nonlymphocytic leukemia) is a malignancy of the myeloid line of blood cells, characterized by the rapid growth of abnormal immature white blood cells (blasts) that accumulate in the bone marrow and interfere with the production of normal blood cells. According to World Health Organization (WHO) criteria, a diagnosis of AML is established by demonstrating presence of 20% or more blasts in the blood and/or bone marrow [<xref rid="pone.0132736.ref001" ref-type="bibr">1</xref>]. AML is more common in adults, in whom the incidence rises steeply after the age of 55&#x2013;60 years. The median age is 65 years and men are more often affected than women [<xref rid="pone.0132736.ref002" ref-type="bibr">2</xref>].</p>
      <p>Chromosome banding analysis of bone marrow cells has revealed acquired clonal chromosomal rearrangements in most AML patients. The types of aberrations and the frequency with which they are found are influenced by factors such as age, previous treatment or other exposure to genotoxics, gender, ethnic or geographic origin, and constitutional genetics [<xref rid="pone.0132736.ref003" ref-type="bibr">3</xref>]. Structural chromosomal aberrations in AML such as translocations, inversions, and deletions often result in the generation of a fusion gene, i.e., a hybrid gene formed from two previously separate genes, which affects cellular pathways of myeloid maturation and proliferation [<xref rid="pone.0132736.ref003" ref-type="bibr">3</xref>]. In the WHO classification of AML (and myeloid neoplasms in general), the chromosomal rearrangements/fusion genes play an important role in the grouping of AMLs into diagnostic-prognostic-therapeutic entities; for example, rearrangements such as t(8;21)(q22;q22) (fusion gene <italic>RUNX1-RUNX1T1</italic>), inv(16)(p13.1q22) (fusion gene <italic>CBFB-MYH11</italic>), and t(15;17)(q22;q12) (fusion gene <italic>PML-RARA</italic>) define specific AML subsets and their finding is sufficient for an AML diagnosis regardless of the blast percentage in the blood or bone marrow [<xref rid="pone.0132736.ref001" ref-type="bibr">1</xref>]. The three above-mentioned chromosomal aberrations/fusion genes are also associated with favorable prognosis [<xref rid="pone.0132736.ref003" ref-type="bibr">3</xref>] whereas others, e.g., <italic>KAT6A-CREBBP</italic>, the result of a t(8;16)(p11;p13) chromosomal translocation, are associated with poor prognosis [<xref rid="pone.0132736.ref004" ref-type="bibr">4</xref>]. Furthermore, fusion genes can be the targets of specific molecular therapy, the paradigmatic example being the use of all-trans retinoic acid (ATRA)/arsenic trioxide (ATO) in the treatment of acute promyelocytic leukemia (APL) carrying the <italic>PML&#x2014;RARA</italic> fusion which is key to APL leukemogenesis generated by t(15;17) [<xref rid="pone.0132736.ref005" ref-type="bibr">5</xref>]. Hence, the identification and characterization of novel leukemia-specific fusion genes and the study of their effects on cellular processes have clinical significance.</p>
      <p>The &#x201C;traditional&#x201D; methodology to detect fusion genes in cancer begins with cytogenetic analysis to find the chromosomal rearrangement, followed by utilization of fluorescence in situ hybridization (FISH) techniques to find a probe which spans the chromosomal breakpoint. Eventually, molecular cloning is performed to localize the breakpoint more precisely and identify the genes fused by the chromosomal rearrangement. Although laborious, the above-mentioned sequential approach is quite robust and reliable and a number of fusion genes have been cloned by such means [<xref rid="pone.0132736.ref003" ref-type="bibr">3</xref>]. The introduction of next generation sequencing has opened up new possibilities to detect fusion genes in cancer [<xref rid="pone.0132736.ref006" ref-type="bibr">6</xref>]. The search for fusion genes presently in the main proceeds along two main axes, either using brute molecular genetic force (i.e., high throughput sequencing) in the common cancers where cytogenetic guidance is sparse at best, or by combination of cytogenetics and sequencing so that the karyotypic information can be used to select among the numerous candidate fusion genes offered by the latter method to find only those few that map to chromosomal breakpoints [<xref rid="pone.0132736.ref007" ref-type="bibr">7</xref>]. The actual presence of the fusion genes thus detected is then confirmed by other molecular genetic (PCR and Sanger sequencing analyses) and molecular cytogenetic methods (FISH).</p>
      <p>We and others have used combinations of cytogenetics and RNA-sequencing to detect the fusion genes associated with acquired cancer-specific chromosomal rearrangements [<xref rid="pone.0132736.ref007" ref-type="bibr">7</xref>]. These fusion genes were considered to be primary tumorigenic events because the chromosomal rearrangements generating them were often seen as the sole aberration by cytogenetic analysis.</p>
      <p>Recently, a recurrent t(2;14)(q22;q32) chromosomal translocation was reported in immature early T-cell precursor leukemia (ETP-ALL) [<xref rid="pone.0132736.ref008" ref-type="bibr">8</xref>]. Using FISH, the translocation was shown to affect the <italic>BCL11B</italic> and <italic>ZEB2</italic> loci on chromosome bands 14q32 and 2q22, respectively, resulting in overexpression of <italic>ZEB2</italic>. However, neither <italic>BCL11B-ZEB2</italic> nor <italic>ZEB2-BCL11B</italic> (nor their respective fusion transcripts) was demonstrated in that study.</p>
      <p>We here report an AML case carrying the same t(2;14)(q22;q32) chromosomal translocation in bone marrow cells as that reported in ETP-ALL. Using RNA-sequencing, the translocation was shown to result in generation of a <italic>ZEB2-BCL11B</italic> fusion gene.</p>
    </sec>
    <sec sec-type="materials|methods" id="sec002">
      <title>Materials and Methods</title>
      <sec id="sec003">
        <title>Ethical approval</title>
        <p>The study was approved by the Regional Committee for Medical and Health Research Ethics, South-East Norway (REK S&#xF8;r) <ext-link ext-link-type="uri" xlink:href="http://helseforskning.etikkom.no">http://helseforskning.etikkom.no</ext-link>). Written informed consent was obtained from the patient prior to his death. The consent sought from the participant included consent for the publication of his clinical details. The ethics committee&#x2019;s approval included a review of the consent procedure. All patient information has been anonymized and de-identified.</p>
      </sec>
      <sec id="sec004">
        <title>Patient</title>
        <p>A 28-year-old man was transferred to our institution with a diagnosis of AML (<xref rid="pone.0132736.t001" ref-type="table">Table 1</xref> and <xref rid="pone.0132736.g001" ref-type="fig">Fig 1A</xref>). He presented with signs of infection (fever and cough) and a remarkable swelling on the neck with slight rubor and tenderness. Computer tomography (CT) demonstrated bilateral massive lymphadenopathy with necrosis. His AML turned out to be chemoresistant as he failed three induction courses (<xref rid="pone.0132736.t001" ref-type="table">Table 1</xref>). Further leukemia-directed treatment was therefore discontinued, and the patient succumbed within short of infections.</p>
        <fig id="pone.0132736.g001" orientation="portrait" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0132736.g001</object-id>
          <label>Fig 1</label>
          <caption>
            <title>Hematological and cytogenetic data on the AML patient with t(2;14).</title>
            <p>A) Blasts without granulation and with relatively little cytoplasm in the patient&#xB4;s bone marrow. B) Partial karyotype showing the der(2)t(2;14)(q22;q32) and der(14)t(2;14)(q22;q32) together with the corresponding normal chromosome homologs; breakpoint positions are indicated by arrows.</p>
          </caption>
          <graphic xlink:href="pone.0132736.g001"/>
        </fig>
        <table-wrap id="pone.0132736.t001" orientation="portrait" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0132736.t001</object-id>
          <label>Table 1</label>
          <caption>
            <title>Hematological data and treatment on the AML patient with the t(2;14) chromosomal aberration.</title>
          </caption>
          <alternatives>
            <graphic id="pone.0132736.t001g" xlink:href="pone.0132736.t001"/>
            <table frame="hsides" rules="groups">
              <colgroup span="1">
                <col align="left" valign="middle" span="1"/>
                <col align="left" valign="middle" span="1"/>
                <col align="left" valign="middle" span="1"/>
                <col align="left" valign="middle" span="1"/>
                <col align="left" valign="middle" span="1"/>
                <col align="left" valign="middle" span="1"/>
                <col align="left" valign="middle" span="1"/>
                <col align="left" valign="middle" span="1"/>
                <col align="left" valign="middle" span="1"/>
              </colgroup>
              <thead>
                <tr>
                  <th colspan="2" align="center" rowspan="1">Blood analysis</th>
                  <th colspan="2" align="center" rowspan="1">Smear</th>
                  <th colspan="2" align="center" rowspan="1">Molecular genetic analysis in BM</th>
                  <th colspan="2" align="center" rowspan="1">Immunophenotype in BM</th>
                  <th align="left" rowspan="1" colspan="1">Treatment</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>Hb</bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">8.0 g/dL (13.4&#x2013;17.0)</td>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>BM</bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">90% blasts with a sparse cytoplasmic brim and no granulation</td>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>Positive</bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">FLT3-ITD</td>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>Positive</bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">Strongly CD34+ and CD117+ (88%)</td>
                  <td align="left" rowspan="1" colspan="1">1. Idarubicin 12mg/m<sup>2</sup> day 1&#x2013;3, cytarabin 200 mg/m<sup>2</sup> day 1&#x2013;7</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>Plc</bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">291 x 10<sup>9</sup>/L (145&#x2013;390)</td>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>PB</bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">85% blasts</td>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>Negative</bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">FLT3-TKD, EVI-1, CEBPalfa, NPM1, CBFB-MYH11, RUNX1-RUNX1T1</td>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>Coexpression</bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">HLA-DR, CD38, CD13, CD71, CD7, Tdt</td>
                  <td align="left" rowspan="1" colspan="1">2. Cytarabin 1g/m<sup>2</sup> x 2 day 1&#x2013;6, amsakrin 120 mg/m<sup>2</sup> day 4&#x2013;6</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>WBC</bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">29.7 x 10<sup>9</sup>/L (3.5&#x2013;10)</td>
                  <td rowspan="2" align="left" colspan="1"/>
                  <td rowspan="2" align="left" colspan="1"/>
                  <td rowspan="2" align="left" colspan="1"/>
                  <td rowspan="2" align="left" colspan="1"/>
                  <td rowspan="2" align="left" colspan="1"/>
                  <td rowspan="2" align="left" colspan="1"/>
                  <td rowspan="2" align="left" colspan="1">3. Amsakrin 150 mg/m<sup>2</sup> day 1&#x2013;5, etoposide 110 mg/m<sup>2</sup> day 1&#x2013;5, cytarabin 200 mg/m<sup>2</sup> day 1&#x2013;5</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>LD</bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">677 U/L (105&#x2013;205)</td>
                </tr>
              </tbody>
            </table>
          </alternatives>
          <table-wrap-foot>
            <fn id="t001fn001">
              <p>Hb, hemoglobin; Plc, platelet count; WBC, white bloood cells; LD, lactate dehydrogenase; BM, bone marrow; PB, peripheral blood.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="sec005">
        <title>Control samples</title>
        <p>Two controls were used: A previously reported AML with karyotype at diagnosis 46,XY,add(1)(p13),t(8;21)(p11;q22),der(16)t(1;16)(p13;p13)[9]/46,XY[1] which was shown to carry a cryptic <italic>KAT6A-CREBBP</italic> fusion gene [<xref rid="pone.0132736.ref009" ref-type="bibr">9</xref>], and human bone marrow total RNA (Clontech Laboratories, Inc., Mountainview, CA, USA). According to the company&#x2019;s information, it is a mixture of normal bone marrow pooled from 6 male/female Caucasians, ages: 38&#x2013;59.</p>
      </sec>
      <sec id="sec006">
        <title>G-banding and karyotyping</title>
        <p>Bone marrow cells were cytogenetically investigated by standard methods. Chromosome preparations were made from metaphase cells of a 24-hours culture, G-banded using Leishman stain, and karyotyped according to ISCN 2009 guidelines [<xref rid="pone.0132736.ref010" ref-type="bibr">10</xref>].</p>
      </sec>
      <sec id="sec007">
        <title>RNA-sequencing</title>
        <p>Total RNA was extracted from the patient&#x2019;s bone marrow at the time of diagnosis using miRNeasy Mini Kit according to the manufacturer&#x2019;s instructions (Qiagen Nordic, Oslo, Norway). Subsequently, total RNA was purified using QIAcube (Qiagen). The RNA quality was evaluated using the Experion Automated Electrophoresis System (Bio-Rad Laboratories, Oslo, Norway). The RNA Quality Indicator (RQI) was 7.8. Three &#x3BC;g of total RNA were sent for high-throughput paired-end RNA-sequencing at the Norwegian Sequencing Centre, Ullev&#xE5;l Hospital (<ext-link ext-link-type="uri" xlink:href="http://www.sequencing.uio.no/">http://www.sequencing.uio.no/</ext-link>). The RNA was sequenced using an Illumina HiSeq 2000 instrument and the Illumina software pipeline was used to process image data into raw sequencing data. The TruSeq Stranded mRNA sample preparation protocol was used (<ext-link ext-link-type="uri" xlink:href="http://support.illumina.com/downloads/truseq_stranded_mrna_sample_preparation_guide_15031047.ilmn">http://support.illumina.com/downloads/truseq_stranded_mrna_sample_preparation_guide_15031047.ilmn</ext-link>) giving reads of a length of 100 base pairs. A total of 70 million reads were obtained. The quality of the raw sequence data was assessed using FastQC software (<ext-link ext-link-type="uri" xlink:href="http://www.bioinformatics.babraham.ac.uk/projects/fastqc/">http://www.bioinformatics.babraham.ac.uk/projects/fastqc/</ext-link>). Two softwares were used for the discovery of fusion transcripts: FusionCatcher (version 0.99.3a beta-April 15, 2014) with the associated ENSEMBL, UCSC, and RefSeq databases automatically downloaded by FusionCatcher (<ext-link ext-link-type="uri" xlink:href="https://code.google.com/p/fusioncatcher/">https://code.google.com/p/fusioncatcher/</ext-link>) [<xref rid="pone.0132736.ref011" ref-type="bibr">11</xref>] and ChimeraScan (<ext-link ext-link-type="uri" xlink:href="https://code.google.com/p/chimerascan/">https://code.google.com/p/chimerascan/</ext-link>) [<xref rid="pone.0132736.ref012" ref-type="bibr">12</xref>]. To verify further the fusion genes which were found by FusionCatcher and ChimeraScan, the &#x201C;grep&#x201D; command (<ext-link ext-link-type="uri" xlink:href="http://en.wikipedia.org/wiki/Grep">http://en.wikipedia.org/wiki/Grep</ext-link>) was used to search the fastq files of the sequence data (<ext-link ext-link-type="uri" xlink:href="http://en.wikipedia.org/wiki/FASTQ_format">http://en.wikipedia.org/wiki/FASTQ_format</ext-link>). Our &#x201C;specific expression&#x201D; was a sequence of 20 nucleotides at the fusion point, 10 bases upstream (5&#xB4;-end gene), and 10 bases downstream from the junction (3&#xB4;-end gene). The expressions were: "<monospace>AGGAAAAACGCAGAGGCTGA</monospace>" (type 1), "<monospace>AGGAAAAACGAGGCTGACCA</monospace>" (type 2), "<monospace>GACTTCGCAGAGGCTGACCA</monospace>" (type 3), and "<monospace>AGGAAAAACGAGCACAAAAG</monospace>" (type 4) for the four alternative fusion transcripts of <italic>ZEB2-BCL11B</italic> which were found with FusionCatcher (see <xref rid="pone.0132736.s001" ref-type="supplementary-material">S1 Table</xref>). The sequences obtained by &#x201C;grep&#x201D; were blasted against the human genomic plus transcript database (<ext-link ext-link-type="uri" xlink:href="http://blast.ncbi.nlm.nih.gov/Blast.cgi">http://blast.ncbi.nlm.nih.gov/Blast.cgi</ext-link>) as well as the reference sequences NM_014795.3 (<italic>ZEB2</italic>) and NM_022898.2 (<italic>BCL11B</italic>).</p>
        <sec id="sec008">
          <title>RT-PCR analysis</title>
          <p>The primers used for PCR amplification and Sanger sequencing are listed in <xref rid="pone.0132736.t002" ref-type="table">Table 2</xref>.</p>
          <table-wrap id="pone.0132736.t002" orientation="portrait" position="float">
            <object-id pub-id-type="doi">10.1371/journal.pone.0132736.t002</object-id>
            <label>Table 2</label>
            <caption>
              <title>Primers used for PCR amplification and Sanger sequencing analyses.</title>
            </caption>
            <alternatives>
              <graphic id="pone.0132736.t002g" xlink:href="pone.0132736.t002"/>
              <table frame="hsides" rules="groups">
                <colgroup span="1">
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                </colgroup>
                <thead>
                  <tr>
                    <th align="left" rowspan="1" colspan="1">Name</th>
                    <th align="left" rowspan="1" colspan="1">Sequence (5&#xB4;-&gt;3&#xB4;)</th>
                    <th align="left" rowspan="1" colspan="1">Direction</th>
                    <th align="left" rowspan="1" colspan="1">Position / Exon</th>
                    <th align="left" rowspan="1" colspan="1">Reference Sequence</th>
                    <th align="left" rowspan="1" colspan="1">Gene</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">ZEB2-383F1</td>
                    <td align="left" rowspan="1" colspan="1">
                      <monospace>CACACTTCGCGGCTTCTTCATGCTT</monospace>
                    </td>
                    <td align="left" rowspan="1" colspan="1">Forward</td>
                    <td align="left" rowspan="1" colspan="1">383&#x2013;407 / 1</td>
                    <td align="left" rowspan="1" colspan="1">NM_014795.3</td>
                    <td align="left" rowspan="1" colspan="1">
                      <italic>ZEB2</italic>
                    </td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">ZEB2-485F1</td>
                    <td align="left" rowspan="1" colspan="1">
                      <monospace>CGAGTCCATGCGAACTGCCATCTG</monospace>
                    </td>
                    <td align="left" rowspan="1" colspan="1">Forward</td>
                    <td align="left" rowspan="1" colspan="1">485&#x2013;508 / 2</td>
                    <td align="left" rowspan="1" colspan="1">NM_014795.3</td>
                    <td align="left" rowspan="1" colspan="1">
                      <italic>ZEB2</italic>
                    </td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">ZEB2-672R1</td>
                    <td align="left" rowspan="1" colspan="1">
                      <monospace>TGGTCCAGAGGGTTGGCAATACCG</monospace>
                    </td>
                    <td align="left" rowspan="1" colspan="1">Reverse</td>
                    <td align="left" rowspan="1" colspan="1">695&#x2013;672 / 3</td>
                    <td align="left" rowspan="1" colspan="1">NM_014795.3</td>
                    <td align="left" rowspan="1" colspan="1">
                      <italic>ZEB2</italic>
                    </td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">ZEB2-985R1</td>
                    <td align="left" rowspan="1" colspan="1">
                      <monospace>GCTGACTGCATGACCATCGCGTTC</monospace>
                    </td>
                    <td align="left" rowspan="1" colspan="1">Reverse</td>
                    <td align="left" rowspan="1" colspan="1">985&#x2013;1008 / 5</td>
                    <td align="left" rowspan="1" colspan="1">NM_014795.3</td>
                    <td align="left" rowspan="1" colspan="1">
                      <italic>ZEB2</italic>
                    </td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">BCL11B-464F1</td>
                    <td align="left" rowspan="1" colspan="1">
                      <monospace>CTCCGGGCGATGCCAGAATAGATG</monospace>
                    </td>
                    <td align="left" rowspan="1" colspan="1">Forward</td>
                    <td align="left" rowspan="1" colspan="1">464&#x2013;487 / 1</td>
                    <td align="left" rowspan="1" colspan="1">NM_022898.2</td>
                    <td align="left" rowspan="1" colspan="1">
                      <italic>BCL11B</italic>
                    </td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">BCL11B-654R1</td>
                    <td align="left" rowspan="1" colspan="1">
                      <monospace>CACTGGCCACAGGTGAGCAGGTCA</monospace>
                    </td>
                    <td align="left" rowspan="1" colspan="1">Reverse</td>
                    <td align="left" rowspan="1" colspan="1">677&#x2013;654 / 2</td>
                    <td align="left" rowspan="1" colspan="1">NM_022898.2</td>
                    <td align="left" rowspan="1" colspan="1">
                      <italic>BCL11B</italic>
                    </td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">BCL11B-969R1</td>
                    <td align="left" rowspan="1" colspan="1">
                      <monospace>GCAGGAACCACGCGCTGTTGAAG</monospace>
                    </td>
                    <td align="left" rowspan="1" colspan="1">Reverse</td>
                    <td align="left" rowspan="1" colspan="1">991&#x2013;969 / 3</td>
                    <td align="left" rowspan="1" colspan="1">NM_022898.2</td>
                    <td align="left" rowspan="1" colspan="1">
                      <italic>BCL11B</italic>
                    </td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">ABL1-91F1</td>
                    <td align="left" rowspan="1" colspan="1">
                      <monospace>CAGCGGCCAGTAGCATCTGACTTTG</monospace>
                    </td>
                    <td align="left" rowspan="1" colspan="1">Forward</td>
                    <td align="left" rowspan="1" colspan="1">280&#x2013;304 / 2</td>
                    <td align="left" rowspan="1" colspan="1">NM_005157.5</td>
                    <td align="left" rowspan="1" colspan="1">
                      <italic>ABL1</italic>
                    </td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">ABL1-404R1</td>
                    <td align="left" rowspan="1" colspan="1">
                      <monospace>CTCAGCAGATACTCAGCGGCATTGC</monospace>
                    </td>
                    <td align="left" rowspan="1" colspan="1">Reverse</td>
                    <td align="left" rowspan="1" colspan="1">617&#x2013;593 / 3</td>
                    <td align="left" rowspan="1" colspan="1">NM_005157.5</td>
                    <td align="left" rowspan="1" colspan="1">
                      <italic>ABL1</italic>
                    </td>
                  </tr>
                </tbody>
              </table>
            </alternatives>
          </table-wrap>
          <p>For RT-PCR, one &#x3BC;g of total RNA was reverse-transcribed in a 20 &#x3BC;L reaction volume using iScript Advanced cDNA Synthesis Kit for RT-qPCR according to the manufacturer&#x2019;s instructions (Bio-Rad Laboratories, Oslo, Norway). The 25 &#x3BC;L PCR volume contained 12.5 &#x3BC;L Premix Ex Taq DNA Polymerase Hot Start Version (Takara Bio Europe/SAS, Saint-Germain-en-Laye, France), 1 &#x3BC;L of cDNA, and 0.4 &#x3BC;M of each of the forward and reverse primer. The primer sets ZEB2-383F1/BCL11B-654R1 and ZEB2-485F1/BCL11B-654R1 were used to detect possible <italic>ZEB2-BCL11B</italic> fusion transcripts. The primer sets BCL11B-464F1/ZEB2-985R1 and BCL11B-464F1/ZEB2-672R1 were used to detect possible <italic>BCL11B-ZEB2</italic> fusion transcripts. To detect the expression of the normal <italic>ZEB2</italic> gene, the primer set ZEB2-383F1/ZEB2-985R1 was used. To detect expression of the normal <italic>BCL11B</italic> gene, the primer set BCL11B-464F1/BCL11B-969R1 was used. The quality of the cDNA synthesis was examined by amplification of a cDNA fragment of the <italic>ABL1</italic> gene using the primers ABL1-91F1 and ABL1-404R1. The PCR amplifications were run on a C-1000 Thermal cycler (Bio-Rad Laboratories) with an initial denaturation at 94&#xB0;C for 30 sec, followed by 35 cycles of 7 sec at 98&#xB0;C, 2 min at 68&#xB0;C, and a final extension for 5 min at 68&#xB0;C. Three &#x3BC;L of the PCR products were stained with GelRed (Biotium, Hayward, CA, USA), analysed by electrophoresis through 1.0% agarose gel, and photographed. The remaining 22 &#x3BC;L PCR products were purified using the MinElute PCR purification kit (Qiagen Nordic, Oslo, Norway) and sequenced at GATC Biotech (Germany, <ext-link ext-link-type="uri" xlink:href="http://www.gatc-biotech.com/en/home.html">http://www.gatc-biotech.com/en/home.html</ext-link>). The BLAST software (<ext-link ext-link-type="uri" xlink:href="http://blast.ncbi.nlm.nih.gov/Blast.cgi">http://blast.ncbi.nlm.nih.gov/Blast.cgi</ext-link>) was used for computer analysis of sequence data.</p>
        </sec>
      </sec>
    </sec>
    <sec sec-type="results" id="sec009">
      <title>Results</title>
      <sec id="sec010">
        <title>G-banding</title>
        <p>G-banding analysis of bone marrow cells at diagnosis showed two cytogenetically related subclones. In the first subclone, five cells carried the chromosomal translocation t(2;14)(q22;q32) as the sole cytogenetic abnormality (<xref rid="pone.0132736.g001" ref-type="fig">Fig 1B</xref>). In the second subclone, six cells carried an extra chromosome, presumably #4, and an interstitial deletion in chromosome 6 together with the above-mentioned translocation. Thus, G-banding analysis of bone marrow cells at diagnosis indicated that t(2;14)(q22;q32) was the primary cytogenetic abnormality. The resulting karyotype was 46,XY,t(2;14)(q22;q32)[5]/47,XY,idem,+?4,del(6)(q13q21)[cp6]/46,XY[4].</p>
      </sec>
      <sec id="sec011">
        <title>RNA-sequencing</title>
        <p>Using FusionCatcher on the raw sequencing data obtained from the Genomics Core Facility, 103 potential fusion transcripts were found (<xref rid="pone.0132736.s001" ref-type="supplementary-material">S1 Table</xref>), among them the <italic>ZEB2-BCL11B</italic>. Using ChimeraScan with the same fastq file, 263 potential fusion transcripts were found (<xref rid="pone.0132736.s002" ref-type="supplementary-material">S2 Table</xref>), among them the <italic>ZEB2-BCL11B</italic>. Neither FusionCatcher nor ChimeraScan found the reciprocal <italic>BCL11B-ZEB2</italic> (<xref rid="pone.0132736.s001" ref-type="supplementary-material">S1</xref> and <xref rid="pone.0132736.s002" ref-type="supplementary-material">S2</xref> Tables).</p>
        <p>Further analysis of the fusion transcripts identified with the two softwares showed that FusionCatcher identified four types (types 1&#x2013;4) of <italic>ZEB2-BCL11B</italic> (<xref rid="pone.0132736.s001" ref-type="supplementary-material">S1 Table</xref>). Type 1 corresponds to the fusion of exon 2 of <italic>ZEB2</italic> with exon 2 of <italic>BCL11B</italic>. Type 2 corresponds to the same fusion but without the first three, CAG, nucleotides of exon 2 of <italic>BCL11B</italic>. Type 3 corresponds to the fusion of exon 1 of <italic>ZEB2</italic> with exon 2 of <italic>BCL11B</italic> without the first three bases, CAG, of exon 2 of <italic>BCL11B</italic>. Type 4 corresponds to the fusion of exon 2 of <italic>ZEB2</italic> with nt 719 within exon 2 of <italic>BCL11B</italic>. Only the type 1 <italic>ZEB2-BCL11B</italic> fusion transcript was found by ChimeraScan (<xref rid="pone.0132736.s002" ref-type="supplementary-material">S2 Table</xref>).</p>
        <p>In order to verify the fusion obtained with the FusionCatcher and ChimeraScan softwares, we used the &#x201C;grep&#x201D; command utility to search for expressions composed of 10 nt of <italic>ZEB2</italic> and 10 nt of <italic>BCL11B</italic> upstream and downstream of the fusion point (<xref rid="pone.0132736.t003" ref-type="table">Table 3</xref>). Using the expression "<monospace>AGGAAAAACGCAGAGGCTGA</monospace>", which is composed of 10 nt, "<monospace>AGGAAAAACG</monospace>", from <italic>ZEB2</italic> and 10 nt, "<monospace>CAGAGGCTGA</monospace>", from <italic>BCL11B</italic>, 18 sequences were retrieved. With the expression "<monospace>AGGAAAAACGAGGCTGACCA</monospace>", which is composed of 10 nt, "<monospace>AGGAAAAACG</monospace>", from <italic>ZEB2</italic> and 10 nt, "<monospace>AGGCTGACCA</monospace>", from <italic>BCL11B</italic>, 4 sequences were retrieved. The expression "<monospace>GACTTCGCAGAGGCTGACCA</monospace>", which is composed of 10 nt, "<monospace>GACTTCGCAG</monospace>", from <italic>ZEB2</italic> and 10 nt, "<monospace>AGGCTGACCA</monospace>", from <italic>BCL11B</italic>, retrieved 2 sequences. Finally, "<monospace>AGGAAAAACGAGCACAAAAG</monospace>", which is composed of the 10 nt "<monospace>AGGAAAAACG</monospace>" from <italic>ZEB2</italic> and the 10 nt "<monospace>AGCACAAAAG</monospace>" from <italic>BCL11B</italic>, retrieved 1 sequence (<xref rid="pone.0132736.t003" ref-type="table">Table 3</xref>).</p>
        <table-wrap id="pone.0132736.t003" orientation="portrait" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0132736.t003</object-id>
          <label>Table 3</label>
          <caption>
            <title>Sequences retrieved with the &#xAB;grep&#xBB; command using the expressions "<monospace>AGGAAAAACGCAGAGGCTGA</monospace>", "<monospace>AGGAAAAACGAGGCTGACCA</monospace>", "<monospace>GACTTCGCAGAGGCTGACCA</monospace>", and "<monospace>AGGAAAAACGAGCACAAAAG</monospace>" which correspond to type 1, type 2, type 3 and type 4 of <italic>ZEB2-BCL11B</italic> fusion transcript, respectively.</title>
            <p>The sequences of <italic>BCL11B</italic> are in bold.</p>
          </caption>
          <alternatives>
            <graphic id="pone.0132736.t003g" xlink:href="pone.0132736.t003"/>
            <table frame="hsides" rules="groups">
              <colgroup span="1">
                <col align="left" valign="middle" span="1"/>
                <col align="left" valign="middle" span="1"/>
              </colgroup>
              <thead>
                <tr>
                  <th align="left" rowspan="1" colspan="1">Type (expression)</th>
                  <th align="left" rowspan="1" colspan="1">Sequences</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td rowspan="17" align="left" colspan="1">Type 1 (<monospace>AGGAAAAACG <bold>CAGAGGCTGA</bold></monospace>)</td>
                  <td align="left" rowspan="1" colspan="1">
                    <monospace>ATCCGCTCTTATCAATGAAGCAGCCGATCATGGCGGATGGCCCCCGGTGCAAGAGGCGCAAACAAGCCAATCCCAGGAGGAAAAACG<bold>CAGAGGCTGACCAT</bold></monospace>
                  </td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <monospace>CAAACAAGCCAATCCCAGGAGGAAAAACG<bold>CAGAGGCTGACCATGTGGAGGCCGCCATCCTCGAAGAAGACGAGGGTCTGGAGATAGAGGAGCCAAGTGGCC</bold></monospace>
                  </td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <monospace>CCAGGAGGAAAAACG<bold>CAGAGGCTGACCATGTGGAGGCCGCCATCCTCGAAGAAGACGAGGGTCTGGAGATAGAGGAGCCAAGTGGCCTGGGGCTGATGGTG</bold></monospace>
                  </td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <monospace>ATCCCAGGAGGAAAAACG<bold>CAGAGGCTGACCATGTGGAGGCCGCCATCCTCGAAGAAGACGAGGGTCTGGAGATAGAGGAGCCAAGTGGCCTGGGGCTGATG</bold></monospace>
                  </td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <monospace>CAGGAGGAAAAACG<bold>CAGAGGCTGACCATGTGGAGGCCGCCATCCTCGAAGAAGACGAGGGTCTGGAGATAGAGGAGCCAAGTGGCCTGGGGCTGATGGTGG</bold></monospace>
                  </td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <monospace>AGGAGGAAAAACG<bold>CAGAGGCTGACCATGTGGAGGCCGCCATCCTCGAAGAAGACGAGGAGCACAAAAGGAAGCAGTGTGGCGGCAGCTTGGGTGCCTGCTA</bold></monospace>
                  </td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <monospace>GGCGCAAACAAGCCAATCCCAGGAGGAAAAACG<bold>CAGAGGCTGACCATGTGGAGGCCGCCATCCTCGAAGAAGACGAGGGTCTGGAGATAGAGGAGCCAAGT</bold></monospace>
                  </td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <monospace>GATCCGCTCTTATCAATGAAGCAGCCGATCATGGCGGATGGCCCCCGGTGCAAGAGGCGCAAACAAGCCAATCCCAGGAGGAAAAACG<bold>CAGAGGCTGACCA</bold></monospace>
                  </td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <monospace>CGGTGCAAGAGGCGCAAACAAGCCAATCCCAGGAGGAAAAACG<bold>CAGAGGCTGACCATGTGGAGGCCGCCATCCTCGAAGAAGACGAGGGTCTGGAGATAGA</bold></monospace>
                  </td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <monospace>ATGGCGGATGGCCCCCGGTGCAAGAGGCGCAAACAAGCCAATCCCAGGAGGAAAAACG<bold>CAGAGGCTGACCATGTGGAGGCCGCCATCCTCGAAGAAGACGA</bold></monospace>
                  </td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <monospace>GGATGGCCCCCGGTGCAAGAGGCGCAAACAAGCCAATCCCAGGAGGAAAAACG<bold>CAGAGGCTGACCATGTGGAGGCCGCCATCCTCGAAGAAGACGAGGGTC</bold></monospace>
                  </td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <monospace>GGCGGATGGCCCCCGGTGCAAGAGGCGCAAACAAGCCAATCCCAGGAGGAAAAACG<bold>CAGAGGCTGACCATGTGGAGGCCGCCATCCTCGAAGAAGACGAGG</bold></monospace>
                    <break/>
                    <monospace>CAAGCCAATCCCAGGAGGAAAAACG<bold>CAGAGGCTGACCATGTGGAGGCCGCCATCCTCGAAGAAGACGAGGGTCTGGAGATAGAGGAGCCAAGTGGCCTGGG</bold></monospace>
                  </td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <monospace>TATCAATGAAGCAGCCGATCATGGCGGATGGCCCCCGGTGCAAGAGGCGCAAACAAGCCAATCCCAGGAGGAAAAACG<bold>CAGAGGCTGACCATGTGGAGGCC</bold></monospace>
                  </td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <monospace>AAGCAGCCGATCATGGCGGATGGCCCCCGGTGCAAGAGGCGCAAACAAGCCAATCCCAGGAGGAAAAACG<bold>CAGAGGCTGACCATGTGGAGGCCGCCATCCT</bold></monospace>
                  </td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <monospace>ATGGCGGATGGCCCCCGGTGCAAGAGGCGCAAACAAGCCAATCCCAGGAGGAAAAACG<bold>CAGAGGCTGACCATGTGGAGGCCGCCATCCTCGAAGAAGACGA</bold></monospace>
                  </td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <monospace>ATGGCGGATGGCCCCCGGTGCAAGAGGCGCAAACAAGCCAATCCCAGGAGGAAAAACG<bold>CAGAGGCTGACCATGTGGAGGCCGCCATCCTCGAAGAAGACGA</bold></monospace>
                  </td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <monospace>CAAGCCAATCCCAGGAGGAAAAACG<bold>CAGAGGCTGACCATGTGGAGGCCGCCATCCTCGAAGAAGACGAGGGTCTGGAGATAGAGGAGCCAAGTGGCCTGGG</bold></monospace>
                  </td>
                </tr>
                <tr>
                  <td rowspan="4" align="left" colspan="1">Type 2 (<monospace>AGGAAAAACG <bold>AGGCTGACCA</bold></monospace>)</td>
                  <td align="left" rowspan="1" colspan="1">
                    <monospace>CAAGCCAATCCCAGGAGGAAAAACG<bold>AGGCTGACCATGTGGAGGCCGCCATCCTCGAAGAAGACGAGGGTCTGGAGATAGAGGAGCCAAGTGGCCTGGGGCT</bold></monospace>
                  </td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <monospace>TCTGATCCGCTCTTATCAATGAAGCAGCCGATCATGGCGGATGGACCCCGGTGCAAGAGGCGCAAACAAGCCAATCCCAGGAGGAAAAACG<bold>AGGCTGACCA</bold></monospace>
                  </td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <monospace>CAAGCCAATCCCAGGAGGAAAAACG<bold>AGGCTGACCATGTGGAGGCCGCCATCCTCGAAGAAGACGAGGGTCTGGAGATAGAGGAGCCAAGTGGCCTGGGGCT</bold></monospace>
                  </td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <monospace>AAACAAGCCAATCCCAGGAGGAAAAACG<bold>AGGCTGACCATGTGGAGGCCGCCATCCTCGAAGAAGACGAGGGTCTGGAGATAGAGGAGCCAAGTGGCCTGGG</bold></monospace>
                  </td>
                </tr>
                <tr>
                  <td rowspan="2" align="left" colspan="1">Type 3 (<monospace>GACTTCGCAG <bold>AGGCTGACCA</bold></monospace>)</td>
                  <td align="left" rowspan="1" colspan="1">
                    <monospace>CTACAAACAAGACTTCGCAG<bold>AGGCTGACCATGTGGAGGCCGCCATCCTCGAAGAAGACGAGGGTCTGGAGATAGAGGAGCCAAGTGGCCTGGGGCTGATGG</bold></monospace>
                  </td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <monospace>GCTTTTTCTTCTCACCATTTCTGGCCAAAACTACAAACAAGACTTCGCAG<bold>AGGCTGACCATGTGGAGGCCGCCATCCTCGAAGAAGACGAGGGTCTGGAGA</bold></monospace>
                  </td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Type 4 (<monospace>AGGAAAAACG <bold>AGCACAAAAG</bold></monospace>)</td>
                  <td align="left" rowspan="1" colspan="1">
                    <monospace>ATGAAGCAGCCGATCATGGCGGATGGCCCCCGGTGCAAGAGGCGCAAACAAGCCAATCCCAGGAGGAAAAACG<bold>AGCACAAAAGGAAGCAGTGTGGCGGCAG</bold></monospace>
                  </td>
                </tr>
              </tbody>
            </table>
          </alternatives>
        </table-wrap>
        <p>Because the <italic>ZEB2</italic> and <italic>BCL11B</italic> genes map to chromosome bands 2q22 and 14q32, respectively, and the chromosomal translocation t(2;14)(q22;q32) was the primary cytogenetic aberration, we decided to investigate further the patient&#x2019;s bone marrow for the presence of the <italic>ZEB2-BCL11B</italic> fusion transcript using molecular techniques. No other fusions were examined.</p>
      </sec>
      <sec id="sec012">
        <title>Molecular Genetic Confirmation of the Fusions</title>
        <p>PCR with the primers ABL1-91F1 and ABL1-404R1 amplified a 338 bp <italic>ABL1</italic> fragment from the cDNAs of the AML-control (patient with <italic>KAT6A-CREBBP</italic> fusion) and the normal bone marrow (<xref rid="pone.0132736.g002" ref-type="fig">Fig 2</xref>). From the cDNA of the patient with t(2;14), two fragments were amplified: 338 bp and 901 bp in size, respectively. The 338 bp fragment corresponds to the processed mRNA (exon 2/exon 3 of <italic>ABL1</italic>) while the 901 bp fragment corresponds to the presence of an unspliced intron 2 (exon 2-intron 2- exon 3) of <italic>ABL1</italic>. The amplified cDNA fragments of <italic>ABL1</italic> indicated that the synthesized cDNAs were of good quality.</p>
        <fig id="pone.0132736.g002" orientation="portrait" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0132736.g002</object-id>
          <label>Fig 2</label>
          <caption>
            <title>RT-PCR amplification.</title>
            <p>Gel electrophoresis for the <italic>ZEB2-BCL11B</italic>, <italic>BCL11B-ZEB2</italic>, <italic>ZEB2</italic>, <italic>BCL11B</italic>, and <italic>ABL1</italic> cDNA transcripts of AML patient with t(2;14), control AML patient with <italic>KAT6A-CREBBP</italic> fusion, and normal bone marrow.</p>
          </caption>
          <graphic xlink:href="pone.0132736.g002"/>
        </fig>
        <p>PCR with the ZEB2-383F1 and BCL11B-654R1 primer combination amplified two cDNA fragments of size 337 bp and 192 bp only from the cDNA of the patient with t(2;14) (<xref rid="pone.0132736.g002" ref-type="fig">Fig 2</xref>). Sanger sequencing of the long, 337 bp, fragment showed that it was a type 1 <italic>ZEB2-BCL11B</italic> chimeric cDNA fragment with the fusion point identical to that found with FusionCatcher, i.e., exon 2 of <italic>ZEB2</italic> (nucleotide 595 in the sequence with accession number NM_014795.3) was fused to exon 2 of <italic>BCL11B</italic> (nucleotide 554 in the sequence with accession number NM_022898.2) (<xref rid="pone.0132736.g003" ref-type="fig">Fig 3A</xref>). Sanger sequencing of the short, 192 bp, fragment showed that it was a type 3 <italic>ZEB2-BCL11B</italic> chimeric cDNA fragment in which the first three bases, CAG, of exon 2 of <italic>BCL11B</italic> were also present, i.e., exon 1 of <italic>ZEB2</italic> (nucleotide 453 in the sequence with accession number NM_014795.3) was fused to exon 2 of <italic>BCL11B</italic> (nucleotide 554 in the sequence with accession number NM_022898.2) (<xref rid="pone.0132736.g003" ref-type="fig">Fig 3B</xref>).</p>
        <fig id="pone.0132736.g003" orientation="portrait" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0132736.g003</object-id>
          <label>Fig 3</label>
          <caption>
            <title>Sanger sequence of the amplified products from the AML patient with the chromosomal aberration t(2;14).</title>
            <p>A) Partial sequence chromatogram of the cDNA fragment showing that exon 2 of <italic>ZEB2</italic> is fused to exon 2 of <italic>BCL11B</italic> (type 1 fusion transcript). B) Partial sequence chromatogram of the cDNA fragment showing that exon 1 of <italic>ZEB2</italic> is fused to exon 2 of <italic>BCL11B</italic> (type 3 fusion transcript). C) Sequence of the amplified cDNA fragment using the primers ZEB2-485F1 and BCL11B-654R1 (shown in box). The fusion point &#x201C;gc&#x201D; is double underlined. The open reading frame is also shown.</p>
          </caption>
          <graphic xlink:href="pone.0132736.g003"/>
        </fig>
        <p>PCR with the ZEB2-485F1 and BCL11B-654R1 primer combination amplified a 235 bp cDNA fragment only from the cDNA of the patient with t(2;14) (<xref rid="pone.0132736.g002" ref-type="fig">Fig 2</xref>). Sanger sequencing showed that it was a type 1 <italic>ZEB2-BCL11B</italic> chimeric cDNA fragment (fusion of exon 2 of <italic>ZEB2</italic> with exon 2 of <italic>BCL11B</italic>) (<xref rid="pone.0132736.g003" ref-type="fig">Fig 3A and 3C</xref>). No cDNA amplified product was obtained when <italic>BCL11B</italic> forward and <italic>ZEB2</italic> reverse primers were used, suggesting that <italic>BCL11B-ZEB2</italic> was absent or not expressed (<xref rid="pone.0132736.g002" ref-type="fig">Fig 2</xref>).</p>
        <p>Normal <italic>ZEB2</italic> cDNA fragments were amplified from the cDNAs of the patient with t(2;14), the AML-control, and the normal bone marrow suggesting that <italic>ZEB2</italic> is expressed in the three samples (<xref rid="pone.0132736.g002" ref-type="fig">Fig 2</xref>). <italic>BCL11B</italic> cDNA fragments were amplified from the cDNAs of the AML-control and the normal bone marrow, whereas no <italic>BCL11B</italic> cDNA fragments were amplified from the patient&#xB4;s cDNA suggesting that <italic>BCL11B</italic> was not expressed or had very low expression in the bone marrow of the patient with t(2;14)-<italic>ZEB2-BCL11B</italic> fusion (<xref rid="pone.0132736.g002" ref-type="fig">Fig 2</xref>).</p>
      </sec>
    </sec>
    <sec sec-type="conclusions" id="sec013">
      <title>Discussion</title>
      <p>We present a case of AML which had FLT3-internal tandem duplication mutation (FLT3-ITD) and cytogenetic aberrations at diagnosis. The primary cytogenetic abnormality was a t(2;14)(q22;q32) chromosomal translocation which rearranged and fused the <italic>ZEB2</italic> gene in 2q22 with the <italic>BCL11B</italic> gene in 14q32. The translocation resulted in the expression of chimeric <italic>ZEB2-BCL11B</italic> transcripts whereas the reciprocal <italic>BCL11B-ZEB2</italic> fusion was either absent or not expressed.</p>
      <p>FLT3-ITD mutation is an important prognostic factor but the prognostic impact must be interpreted against the genetic context [<xref rid="pone.0132736.ref013" ref-type="bibr">13</xref>]. In patients with normal karyotype, FLT3-ITD is associated with poor prognosis [<xref rid="pone.0132736.ref014" ref-type="bibr">14</xref>&#x2013;<xref rid="pone.0132736.ref017" ref-type="bibr">17</xref>]. In acute promyelocytic leukemia with t(15;17), the prognostic impact of FLT3-ITD mutation is minimal [<xref rid="pone.0132736.ref018" ref-type="bibr">18</xref>]. In other contexts, both the mutant to wild type allelic ratio and the position of the ITD within the <italic>FLT3</italic> gene may carry prognostic impact [<xref rid="pone.0132736.ref019" ref-type="bibr">19</xref>, <xref rid="pone.0132736.ref020" ref-type="bibr">20</xref>]. The present case of AML turned out to be chemoresistant as it failed three induction courses. The FLT3-ITD mutations might have played a role in this but so may the presence at diagnosis of the chromosomal aberration t(2;14)(q22;q32) and its molecular consequence, the generation of a <italic>ZEB2-BCL11B</italic>. One cannot at present say which is more prognostically important.</p>
      <p>The same chromosomal translocation as the one we found, t(2;14)(q22;q32), was recently reported in ETP-ALL [<xref rid="pone.0132736.ref008" ref-type="bibr">8</xref>]. In that study, neither <italic>BCL11B-ZEB2</italic> nor <italic>ZEB2-BCL11B</italic> (nor their fusion transcripts) was detected although the translocation was shown to result in overexpression of <italic>ZEB2</italic> [<xref rid="pone.0132736.ref008" ref-type="bibr">8</xref>].</p>
      <p>The <italic>ZEB2</italic> gene (in 2q22) codes for a protein which is a member of the Zfh1 family of 2-handed zinc finger/homeodomain proteins. ZEB2 protein is located in the nucleus and functions as a DNA-binding transcriptional repressor that interacts with activated SMADs, the transducers of TGF-beta signaling, and interacts with the nucleosome remodeling and histone deacetylation (NURD) complex (<ext-link ext-link-type="uri" xlink:href="http://omim.org/entry/605802">http://omim.org/entry/605802</ext-link>). ZEB2 and its paralogue ZEB1 play a pivotal role in vertebrate embryogenesis [<xref rid="pone.0132736.ref021" ref-type="bibr">21</xref>]. Recent evidence shows that both proteins also drive the process of epithelial-mesenchymal transition during cancer progression [<xref rid="pone.0132736.ref022" ref-type="bibr">22</xref>]. The two proteins are involved in the control of several cancer cell capabilities, including proliferation, senescence, apoptosis, angiogenesis, resistance to chemotherapy and radiotherapy, and tumor invasiveness and metastasis [<xref rid="pone.0132736.ref022" ref-type="bibr">22</xref>].</p>
      <p>The <italic>BCL11B</italic> gene and its paralogue <italic>BCL11A</italic> code for krueppel-like C2H2-type zinc finger proteins of the BCL11 family of transcription factors [<xref rid="pone.0132736.ref023" ref-type="bibr">23</xref>]. Although the specific function of <italic>BCL11B</italic> has not been determined, the encoded protein is known to be a bi-functional transcriptional regulator that acts as a repressor and transactivator [<xref rid="pone.0132736.ref024" ref-type="bibr">24</xref>]. BCL11B protein is essential for T-cell development and for maintenance of T-cell identity; in fact, T-cells acquire NK cell properties upon BCL11B deletion [<xref rid="pone.0132736.ref023" ref-type="bibr">23</xref>]. <italic>BCL11B</italic> gene alterations are related to malignant T-cell transformation in hematological malignancies [<xref rid="pone.0132736.ref024" ref-type="bibr">24</xref>]. The fusion genes <italic>BCL11B-TLX3</italic>, <italic>BCL11B-NKX2-5</italic>, <italic>BCL11B-TRD</italic>, and <italic>IKZF2-BCL11B</italic> have all been reported in T-cell acute lymphoblastic leukemia [<xref rid="pone.0132736.ref024" ref-type="bibr">24</xref>]. An <italic>RN28S1-BCL11B</italic> fusion transcript was also identified in a case of mixed-lineage (T/myeloid) acute leukemia with t(6;14)(q25;q32) [<xref rid="pone.0132736.ref025" ref-type="bibr">25</xref>]. The <italic>RN28S1</italic> gene is not translated to protein and <italic>BCL11B</italic> and <italic>RN28S1</italic> were fused in opposite transcription directions. Thus, disruption of the normal functions of <italic>BCL11B</italic> seemed to contribute to leukemogenesis in this case [<xref rid="pone.0132736.ref025" ref-type="bibr">25</xref>]. <italic>BCL11B</italic> was also involved in a case of AML with a similar chromosomal aberration, a t(6;14)(q25~q26;q32), but there was not enough material to identify the partner genomic locus [<xref rid="pone.0132736.ref026" ref-type="bibr">26</xref>]. Very recently, <italic>BCL11B</italic> was shown to be involved in 14q32 translocations with different chromosomal partners in AML [<xref rid="pone.0132736.ref027" ref-type="bibr">27</xref>].</p>
      <p>In the <italic>ZEB2-BCL11B</italic> fusion transcripts 1 and 2, the sequence of <italic>ZEB2</italic> involved codes only for the first 24 amino acids (MKQPIMADGPRCKRRKQANPRRKN) of the ZEB2 protein (starting ATG codon in exon 2, on position 523&#x2013;525 of the <italic>ZEB2</italic> sequence with accession number NM_014795.3) (<xref rid="pone.0132736.g003" ref-type="fig">Fig 3C</xref>). This amino acid sequence does not contain any functional domain except nuclear localization signals (KRRK, PRRK, and PRCKRRK), but replaces the first 19 amino acids of BCL11B (MSRRKQGNPQHLSQRELIT) in the ZEB2-BCL11B chimeric protein. The BCL11B in the ZEB2-BCL11B chimeric protein retains all functional domains, i.e., the 6 krueppel-like Zn-finger domains and the proline-rich region [<xref rid="pone.0132736.ref024" ref-type="bibr">24</xref>]. In the <italic>ZEB2-BCL11B</italic> fusion transcript 3, the untranslated exon 1 of <italic>ZEB2</italic> is fused to exon 2 of <italic>BCL11B</italic>.</p>
      <p>Taking all the data into consideration, i.e., presence of <italic>ZEB2-BCL11B</italic> fusion transcript and absence of <italic>BCL11B-ZEB2</italic> fusion transcript and wild type <italic>BCL11B</italic>, we believe that placing all functional domains of <italic>BCL11B</italic> under the control of the <italic>ZEB2</italic> promoter represents the leukemogenic mechanism for the <italic>ZEB2-BCL11B</italic> chimera. Consequently, the principal result should be abnormal expression of <italic>BCL11B</italic>. Integrative genomic analyses of <italic>ZEB2</italic> showed that the gene&#x2019;s proximal promoter region contains a conserved Ets-Smad-binding CGGAGAC motif as well as bHLH-, POU/OCT-, and HIF1-binding sites [<xref rid="pone.0132736.ref028" ref-type="bibr">28</xref>]. Nevertheless, one cannot rule out the possible importance of the 24 amino acids (MKQPIMADGPRCKRRKQANPRRKN) from ZEB2 in the chimeric protein.</p>
      <p>According to the Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer (<ext-link ext-link-type="uri" xlink:href="http://cgap.nci.nih.gov/Chromosomes/Mitelman">http://cgap.nci.nih.gov/Chromosomes/Mitelman</ext-link>, last updated on May 7, 2015), a t(2;14)(q21;q32) chromosome translocation was reported in three cases of AML and a t(2;14)(q23;q32) in one case. No information is at hand about the molecular consequences of the translocation in the four cases, but we surmise that it could be generation of a <italic>ZEB2-BCL11B</italic> fusion gene. The difference between two neighboring bands (2q21 and 2q22 or 2q22 and 2q23) would be close to or beyond the resolution level of G-banding. Worthy of mention is furthermore that all five patients (including the present case) so far reported with the t(2;14) aberration were male; this may or may not be coincidental.</p>
      <p>In conclusion, we show here that the chromosomal translocation t(2;14)(q22;q32) in AML results in <italic>ZEB2-BCL11B</italic> fusion transcripts the leukemogenic mechanism of which seems to be that the coding regions of the <italic>BCL11B</italic> gene come under the control of the <italic>ZEB2</italic> promoter.</p>
    </sec>
    <sec sec-type="supplementary-material" id="sec014">
      <title>Supporting Information</title>
      <supplementary-material content-type="local-data" id="pone.0132736.s001">
        <label>S1 Table</label>
        <caption>
          <title>Fusion transcripts identified using FusionCatcher.</title>
          <p>Fusion transcripts detected using FusionCatcher.</p>
          <p>(XLSX)</p>
        </caption>
        <media xlink:href="pone.0132736.s001.xlsx">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="pone.0132736.s002">
        <label>S2 Table</label>
        <caption>
          <title>Fusion transcripts identified using ChimeraScan.</title>
          <p>Fusion transcripts detected using ChimeraScan.</p>
          <p>(XLSX)</p>
        </caption>
        <media xlink:href="pone.0132736.s002.xlsx">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="pone.0132736.ref001">
        <label>1</label>
        <mixed-citation publication-type="book"><name><surname>Swerdlow</surname><given-names>SH</given-names></name>, <name><surname>Campo</surname><given-names>E</given-names></name>, <name><surname>Harris</surname><given-names>NL</given-names></name>, <name><surname>Jaffe</surname><given-names>ES</given-names></name>, <name><surname>Pileri</surname><given-names>SA</given-names></name>, <name><surname>Stein</surname><given-names>H</given-names></name>, <etal>et al</etal>
<source>WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues</source>. <edition>4 ed</edition>
<publisher-loc>Lyon</publisher-loc>: <publisher-name>IARC</publisher-name>; <year>2008</year>.</mixed-citation>
      </ref>
      <ref id="pone.0132736.ref002">
        <label>2</label>
        <mixed-citation publication-type="journal"><name><surname>Deschler</surname><given-names>B</given-names></name>, <name><surname>Lubbert</surname><given-names>M</given-names></name>. <article-title>Acute myeloid leukemia: epidemiology and etiology</article-title>. <source>Cancer</source>. <year>2006</year>;<volume>107</volume>(<issue>9</issue>):<fpage>2099</fpage>&#x2013;<lpage>107</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/cncr.22233">10.1002/cncr.22233</ext-link></comment> .<pub-id pub-id-type="pmid">17019734</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0132736.ref003">
        <label>3</label>
        <mixed-citation publication-type="book"><name><surname>Heim</surname><given-names>S</given-names></name>, <name><surname>Mitelman</surname><given-names>F</given-names></name>. <source>Cancer Cytogenetics</source>. <edition>Third Edition</edition> ed: <publisher-name>Wiley-Blackwell</publisher-name>; <year>2009</year>.</mixed-citation>
      </ref>
      <ref id="pone.0132736.ref004">
        <label>4</label>
        <mixed-citation publication-type="journal"><name><surname>Gervais</surname><given-names>C</given-names></name>, <name><surname>Murati</surname><given-names>A</given-names></name>, <name><surname>Helias</surname><given-names>C</given-names></name>, <name><surname>Struski</surname><given-names>S</given-names></name>, <name><surname>Eischen</surname><given-names>A</given-names></name>, <name><surname>Lippert</surname><given-names>E</given-names></name>, <etal>et al</etal>
<article-title>Acute myeloid leukaemia with 8p11 (MYST3) rearrangement: an integrated cytologic, cytogenetic and molecular study by the groupe francophone de cytogenetique hematologique</article-title>. <source>Leukemia</source>. <year>2008</year>;<volume>22</volume>(<issue>8</issue>):<fpage>1567</fpage>&#x2013;<lpage>75</lpage>. Epub 2008/06/06. [pii]. .<pub-id pub-id-type="pmid">18528428</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0132736.ref005">
        <label>5</label>
        <mixed-citation publication-type="journal"><name><surname>Lo-Coco</surname><given-names>F</given-names></name>, <name><surname>Avvisati</surname><given-names>G</given-names></name>, <name><surname>Vignetti</surname><given-names>M</given-names></name>, <name><surname>Thiede</surname><given-names>C</given-names></name>, <name><surname>Orlando</surname><given-names>SM</given-names></name>, <name><surname>Iacobelli</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Retinoic acid and arsenic trioxide for acute promyelocytic leukemia</article-title>. <source>N Engl J Med</source>. <year>2013</year>;<volume>369</volume>(<issue>2</issue>):<fpage>111</fpage>&#x2013;<lpage>21</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1056/NEJMoa1300874">10.1056/NEJMoa1300874</ext-link></comment> .<pub-id pub-id-type="pmid">23841729</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0132736.ref006">
        <label>6</label>
        <mixed-citation publication-type="journal"><name><surname>Annala</surname><given-names>MJ</given-names></name>, <name><surname>Parker</surname><given-names>BC</given-names></name>, <name><surname>Zhang</surname><given-names>W</given-names></name>, <name><surname>Nykter</surname><given-names>M</given-names></name>. <article-title>Fusion genes and their discovery using high throughput sequencing</article-title>. <source>Cancer Lett</source>. <year>2013</year>;<volume>340</volume>(<issue>2</issue>):<fpage>192</fpage>&#x2013;<lpage>200</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.canlet.2013.01.011">10.1016/j.canlet.2013.01.011</ext-link></comment> ; PubMed Central PMCID: PMC3675181.<pub-id pub-id-type="pmid">23376639</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0132736.ref007">
        <label>7</label>
        <mixed-citation publication-type="journal"><name><surname>Panagopoulos</surname><given-names>I</given-names></name>, <name><surname>Thorsen</surname><given-names>J</given-names></name>, <name><surname>Gorunova</surname><given-names>L</given-names></name>, <name><surname>Micci</surname><given-names>F</given-names></name>, <name><surname>Heim</surname><given-names>S</given-names></name>. <article-title>Sequential combination of karyotyping and RNA-sequencing in the search for cancer-specific fusion genes</article-title>. <source>Int J Biochem Cell Biol</source>. <year>2014</year>;<volume>53</volume>:<fpage>462</fpage>&#x2013;<lpage>5</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.biocel.2014.05.018">10.1016/j.biocel.2014.05.018</ext-link></comment> .<pub-id pub-id-type="pmid">24863361</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0132736.ref008">
        <label>8</label>
        <mixed-citation publication-type="journal"><name><surname>Goossens</surname><given-names>S</given-names></name>, <name><surname>Radaelli</surname><given-names>E</given-names></name>, <name><surname>Blanchet</surname><given-names>O</given-names></name>, <name><surname>Durinck</surname><given-names>K</given-names></name>, <name><surname>Van der Meulen</surname><given-names>J</given-names></name>, <name><surname>Peirs</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>ZEB2 drives immature T-cell lymphoblastic leukaemia development via enhanced tumour-initiating potential and IL-7 receptor signalling</article-title>. <source>Nat Commun</source>. <year>2015</year>;<volume>6</volume>:<fpage>5794</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ncomms6794">10.1038/ncomms6794</ext-link></comment> ; PubMed Central PMCID: PMC4354161.<pub-id pub-id-type="pmid">25565005</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0132736.ref009">
        <label>9</label>
        <mixed-citation publication-type="journal"><name><surname>Panagopoulos</surname><given-names>I</given-names></name>, <name><surname>Torkildsen</surname><given-names>S</given-names></name>, <name><surname>Gorunova</surname><given-names>L</given-names></name>, <name><surname>Tierens</surname><given-names>A</given-names></name>, <name><surname>Tjonnfjord</surname><given-names>GE</given-names></name>, <name><surname>Heim</surname><given-names>S</given-names></name>. <article-title>Comparison between karyotyping-FISH-reverse transcription PCR and RNA-sequencing-fusion gene identification programs in the detection of <italic>KAT6A-CREBBP</italic> in acute myeloid leukemia</article-title>. <source>PLoS One</source>. <year>2014</year>;<volume>9</volume>(<issue>5</issue>):<fpage>e96570</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0096570">10.1371/journal.pone.0096570</ext-link></comment> ; PubMed Central PMCID: PMC4010518.<pub-id pub-id-type="pmid">24798186</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0132736.ref010">
        <label>10</label>
        <mixed-citation publication-type="book"><name><surname>Schaffer</surname><given-names>LG</given-names></name>, <name><surname>Slovak</surname><given-names>ML</given-names></name>, <name><surname>Campbell</surname><given-names>LJ</given-names></name>. <source>ISCN 2009: an International System for Human Cytogenetic Nomenclature</source>. <publisher-loc>Basel</publisher-loc>: <publisher-name>Karger</publisher-name>; <year>2009</year>.</mixed-citation>
      </ref>
      <ref id="pone.0132736.ref011">
        <label>11</label>
        <mixed-citation publication-type="journal"><name><surname>Nicorici</surname><given-names>D</given-names></name>, <name><surname>Satalan</surname><given-names>H</given-names></name>, <name><surname>Edgren</surname><given-names>H</given-names></name>, <name><surname>Kangaspeska</surname><given-names>S</given-names></name>, <name><surname>Murumagi</surname><given-names>A</given-names></name>, <name><surname>Kallioniemi</surname><given-names>O</given-names></name>, <etal>et al</etal>
<article-title>FusionCatcher&#x2014;a tool for finding somatic fusion genes in paired-end RNA-sequencing data</article-title>. <source>bioRxiv</source>. <year>2014</year>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1101/011650">10.1101/011650</ext-link></comment></mixed-citation>
      </ref>
      <ref id="pone.0132736.ref012">
        <label>12</label>
        <mixed-citation publication-type="journal"><name><surname>Iyer</surname><given-names>MK</given-names></name>, <name><surname>Chinnaiyan</surname><given-names>AM</given-names></name>, <name><surname>Maher</surname><given-names>CA</given-names></name>. <article-title>ChimeraScan: a tool for identifying chimeric transcription in sequencing data</article-title>. <source>Bioinformatics</source>. <year>2011</year>;<volume>27</volume>(<issue>20</issue>):<fpage>2903</fpage>&#x2013;<lpage>4</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/bioinformatics/btr467">10.1093/bioinformatics/btr467</ext-link></comment> ; PubMed Central PMCID: PMC3187648.<pub-id pub-id-type="pmid">21840877</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0132736.ref013">
        <label>13</label>
        <mixed-citation publication-type="journal"><name><surname>Levis</surname><given-names>M</given-names></name>. <article-title>FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?</article-title>
<source>Hematology Am Soc Hematol Educ Program</source>. <year>2013</year>;<volume>2013</volume>:<fpage>220</fpage>&#x2013;<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1182/asheducation-2013.1.220">10.1182/asheducation-2013.1.220</ext-link></comment> .<pub-id pub-id-type="pmid">24319184</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0132736.ref014">
        <label>14</label>
        <mixed-citation publication-type="journal"><name><surname>Dohner</surname><given-names>H</given-names></name>, <name><surname>Estey</surname><given-names>EH</given-names></name>, <name><surname>Amadori</surname><given-names>S</given-names></name>, <name><surname>Appelbaum</surname><given-names>FR</given-names></name>, <name><surname>Buchner</surname><given-names>T</given-names></name>, <name><surname>Burnett</surname><given-names>AK</given-names></name>, <etal>et al</etal>
<article-title>Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet</article-title>. <source>Blood</source>. <year>2010</year>;<volume>115</volume>(<issue>3</issue>):<fpage>453</fpage>&#x2013;<lpage>74</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1182/blood-2009-07-235358">10.1182/blood-2009-07-235358</ext-link></comment> .<pub-id pub-id-type="pmid">19880497</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0132736.ref015">
        <label>15</label>
        <mixed-citation publication-type="journal"><name><surname>Estey</surname><given-names>EH</given-names></name>. <article-title>Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management</article-title>. <source>Am J Hematol</source>. <year>2012</year>;<volume>87</volume>(<issue>1</issue>):<fpage>89</fpage>&#x2013;<lpage>99</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/ajh.22246">10.1002/ajh.22246</ext-link></comment> .<pub-id pub-id-type="pmid">22180162</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0132736.ref016">
        <label>16</label>
        <mixed-citation publication-type="journal"><name><surname>Estey</surname><given-names>EH</given-names></name>. <article-title>Acute myeloid leukemia: 2013 update on risk-stratification and management</article-title>. <source>Am J Hematol</source>. <year>2013</year>;<volume>88</volume>(<issue>4</issue>):<fpage>318</fpage>&#x2013;<lpage>27</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/ajh.23404">10.1002/ajh.23404</ext-link></comment> .<pub-id pub-id-type="pmid">23526416</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0132736.ref017">
        <label>17</label>
        <mixed-citation publication-type="journal"><name><surname>Estey</surname><given-names>EH</given-names></name>. <article-title>Acute myeloid leukemia: 2014 update on risk-stratification and management</article-title>. <source>Am J Hematol</source>. <year>2014</year>;<volume>89</volume>(<issue>11</issue>):<fpage>1063</fpage>&#x2013;<lpage>81</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/ajh.23834">10.1002/ajh.23834</ext-link></comment> .<pub-id pub-id-type="pmid">25318680</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0132736.ref018">
        <label>18</label>
        <mixed-citation publication-type="journal"><name><surname>Barragan</surname><given-names>E</given-names></name>, <name><surname>Montesinos</surname><given-names>P</given-names></name>, <name><surname>Camos</surname><given-names>M</given-names></name>, <name><surname>Gonzalez</surname><given-names>M</given-names></name>, <name><surname>Calasanz</surname><given-names>MJ</given-names></name>, <name><surname>Roman-Gomez</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy</article-title>. <source>Haematologica</source>. <year>2011</year>;<volume>96</volume>(<issue>10</issue>):<fpage>1470</fpage>&#x2013;<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3324/haematol.2011.044933">10.3324/haematol.2011.044933</ext-link></comment> ; PubMed Central PMCID: PMC3186308.<pub-id pub-id-type="pmid">21685470</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0132736.ref019">
        <label>19</label>
        <mixed-citation publication-type="journal"><name><surname>Kayser</surname><given-names>S</given-names></name>, <name><surname>Schlenk</surname><given-names>RF</given-names></name>, <name><surname>Londono</surname><given-names>MC</given-names></name>, <name><surname>Breitenbuecher</surname><given-names>F</given-names></name>, <name><surname>Wittke</surname><given-names>K</given-names></name>, <name><surname>Du</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome</article-title>. <source>Blood</source>. <year>2009</year>;<volume>114</volume>(<issue>12</issue>):<fpage>2386</fpage>&#x2013;<lpage>92</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1182/blood-2009-03-209999">10.1182/blood-2009-03-209999</ext-link></comment> .<pub-id pub-id-type="pmid">19602710</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0132736.ref020">
        <label>20</label>
        <mixed-citation publication-type="journal"><name><surname>Schlenk</surname><given-names>RF</given-names></name>, <name><surname>Kayser</surname><given-names>S</given-names></name>, <name><surname>Bullinger</surname><given-names>L</given-names></name>, <name><surname>Kobbe</surname><given-names>G</given-names></name>, <name><surname>Casper</surname><given-names>J</given-names></name>, <name><surname>Ringhoffer</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation</article-title>. <source>Blood</source>. <year>2014</year>;<volume>124</volume>(<issue>23</issue>):<fpage>3441</fpage>&#x2013;<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1182/blood-2014-05-578070">10.1182/blood-2014-05-578070</ext-link></comment> .<pub-id pub-id-type="pmid">25270908</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0132736.ref021">
        <label>21</label>
        <mixed-citation publication-type="journal"><name><surname>Vandewalle</surname><given-names>C</given-names></name>, <name><surname>Van Roy</surname><given-names>F</given-names></name>, <name><surname>Berx</surname><given-names>G</given-names></name>. <article-title>The role of the ZEB family of transcription factors in development and disease</article-title>. <source>Cell Mol Life Sci</source>. <year>2009</year>;<volume>66</volume>(<issue>5</issue>):<fpage>773</fpage>&#x2013;<lpage>87</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00018-008-8465-8">10.1007/s00018-008-8465-8</ext-link></comment> .<pub-id pub-id-type="pmid">19011757</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0132736.ref022">
        <label>22</label>
        <mixed-citation publication-type="journal"><name><surname>Sanchez-Tillo</surname><given-names>E</given-names></name>, <name><surname>Siles</surname><given-names>L</given-names></name>, <name><surname>de Barrios</surname><given-names>O</given-names></name>, <name><surname>Cuatrecasas</surname><given-names>M</given-names></name>, <name><surname>Vaquero</surname><given-names>EC</given-names></name>, <name><surname>Castells</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Expanding roles of ZEB factors in tumorigenesis and tumor progression</article-title>. <source>Am J Cancer Res</source>. <year>2011</year>;<volume>1</volume>(<issue>7</issue>):<fpage>897</fpage>&#x2013;<lpage>912</lpage>. ; PubMed Central PMCID: PMC3196287.<pub-id pub-id-type="pmid">22016835</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0132736.ref023">
        <label>23</label>
        <mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>P</given-names></name>, <name><surname>Li</surname><given-names>P</given-names></name>, <name><surname>Burke</surname><given-names>S</given-names></name>. <article-title>Critical roles of Bcl11b in T-cell development and maintenance of T-cell identity</article-title>. <source>Immunol Rev</source>. <year>2010</year>;<volume>238</volume>(<issue>1</issue>):<fpage>138</fpage>&#x2013;<lpage>49</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1600-065X.2010.00953.x">10.1111/j.1600-065X.2010.00953.x</ext-link></comment> .<pub-id pub-id-type="pmid">20969590</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0132736.ref024">
        <label>24</label>
        <mixed-citation publication-type="journal"><name><surname>Huang</surname><given-names>X</given-names></name>, <name><surname>Du</surname><given-names>X</given-names></name>, <name><surname>Li</surname><given-names>Y</given-names></name>. <article-title>The role of BCL11B in hematological malignancy</article-title>. <source>Exp Hematol Oncol</source>. <year>2012</year>;<volume>1</volume>(<issue>1</issue>):<fpage>22</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/2162-3619-1-22">10.1186/2162-3619-1-22</ext-link></comment> ; PubMed Central PMCID: PMC3514087.<pub-id pub-id-type="pmid">23211040</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0132736.ref025">
        <label>25</label>
        <mixed-citation publication-type="journal"><name><surname>Kobayashi</surname><given-names>S</given-names></name>, <name><surname>Taki</surname><given-names>T</given-names></name>, <name><surname>Nagoshi</surname><given-names>H</given-names></name>, <name><surname>Chinen</surname><given-names>Y</given-names></name>, <name><surname>Yokokawa</surname><given-names>Y</given-names></name>, <name><surname>Kanegane</surname><given-names>H</given-names></name>, <etal>et al</etal>
<article-title>Identification of novel fusion genes with 28S ribosomal DNA in hematologic malignancies</article-title>. <source>Int J Oncol</source>. <year>2014</year>;<volume>44</volume>(<issue>4</issue>):<fpage>1193</fpage>&#x2013;<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3892/ijo.2014.2291">10.3892/ijo.2014.2291</ext-link></comment> .<pub-id pub-id-type="pmid">24504345</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0132736.ref026">
        <label>26</label>
        <mixed-citation publication-type="journal"><name><surname>Bezrookove</surname><given-names>V</given-names></name>, <name><surname>van Zelderen-Bhola</surname><given-names>SL</given-names></name>, <name><surname>Brink</surname><given-names>A</given-names></name>, <name><surname>Szuhai</surname><given-names>K</given-names></name>, <name><surname>Raap</surname><given-names>AK</given-names></name>, <name><surname>Barge</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>A novel t(6;14)(q25-q27;q32) in acute myelocytic leukemia involves the BCL11B gene</article-title>. <source>Cancer Genet Cytogenet</source>. <year>2004</year>;<volume>149</volume>(<issue>1</issue>):<fpage>72</fpage>&#x2013;<lpage>6</lpage>. .<pub-id pub-id-type="pmid">15104287</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0132736.ref027">
        <label>27</label>
        <mixed-citation publication-type="journal"><name><surname>Abbas</surname><given-names>S</given-names></name>, <name><surname>Sanders</surname><given-names>MA</given-names></name>, <name><surname>Zeilemaker</surname><given-names>A</given-names></name>, <name><surname>Geertsma-Kleinekoort</surname><given-names>WM</given-names></name>, <name><surname>Koenders</surname><given-names>JE</given-names></name>, <name><surname>Kavelaars</surname><given-names>FG</given-names></name>, <etal>et al</etal>
<article-title>Integrated genome-wide genotyping and gene expression profiling reveals BCL11B as a putative oncogene in acute myeloid leukemia with 14q32 aberrations</article-title>. <source>Haematologica</source>. <year>2014</year>;<volume>99</volume>(<issue>5</issue>):<fpage>848</fpage>&#x2013;<lpage>57</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3324/haematol.2013.095604">10.3324/haematol.2013.095604</ext-link></comment> ; PubMed Central PMCID: PMC4008111.<pub-id pub-id-type="pmid">24441149</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0132736.ref028">
        <label>28</label>
        <mixed-citation publication-type="journal"><name><surname>Katoh</surname><given-names>M</given-names></name>, <name><surname>Katoh</surname><given-names>M</given-names></name>. <article-title>Integrative genomic analyses of ZEB2: Transcriptional regulation of ZEB2 based on SMADs, ETS1, HIF1alpha, POU/OCT, and NF-kappaB</article-title>. <source>Int J Oncol</source>. <year>2009</year>;<volume>34</volume>(<issue>6</issue>):<fpage>1737</fpage>&#x2013;<lpage>42</lpage>. .<pub-id pub-id-type="pmid">19424592</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
